Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 14,500 Shares

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor acquired 14,500 shares of the stock in a transaction dated Monday, November 25th. The shares were purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the purchase, the chief executive officer now owns 152,072 shares of the company's stock, valued at approximately $574,832.16. The trade was a 10.54 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Perspective Therapeutics Stock Up 18.4 %

Shares of NYSE:CATX traded up $0.68 during trading on Tuesday, reaching $4.37. 3,799,963 shares of the stock traded hands, compared to its average volume of 831,321. The firm's 50-day moving average price is $11.15. Perspective Therapeutics, Inc. has a 52-week low of $2.28 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts' consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million for the quarter. As a group, sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the third quarter worth approximately $57,000. US Bancorp DE boosted its holdings in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics in the second quarter worth approximately $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics in the second quarter worth approximately $118,000. Finally, Intech Investment Management LLC purchased a new stake in Perspective Therapeutics in the third quarter worth approximately $137,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on CATX shares. Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They set a "buy" rating and a $21.00 price objective for the company. Bank of America downgraded shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $24.00 to $5.00 in a research note on Monday. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a research note on Friday. Wedbush reissued an "outperform" rating and issued a $11.00 price target (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Finally, Royal Bank of Canada decreased their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating for the company in a research note on Monday. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Perspective Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.